RTOG 92-02 is the largest randomized trial of prostate cancer that tested the optimal duration of ADT when combined with radiation therapy for prostate cancer patients (n=1554 randomized) with T2c–4 primary tumors and PSA <150 ng/ml. This evidence concerns the gene KLK3 and prostate cancer.